Helix BioMedix Inc
Helix BioMedix, Inc., a biotechnology company, develops peptide-based therapeutics for dermatology and skin health in the United States. It is developing HB4208 for treatment of the rare disease Xeroderma Pigmentosum; and BIOACTIVE SMARTPEPTIDES, a bioactive peptide ingredient for skin care companies. The company was founded in 1988 and is based in Bothell, Washington.
Helix BioMedix Inc (HXBM) - Net Assets
Latest net assets as of December 2013: $2.06 Million USD
Based on the latest financial reports, Helix BioMedix Inc (HXBM) has net assets worth $2.06 Million USD as of December 2013.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($2.26 Million) and total liabilities ($202.00K). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $2.06 Million |
| % of Total Assets | 91.06% |
| Annual Growth Rate | 5.32% |
| 5-Year Change | -7.0% |
| 10-Year Change | N/A |
| Growth Volatility | 430.7 |
Helix BioMedix Inc - Net Assets Trend (2000–2024)
This chart illustrates how Helix BioMedix Inc's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Helix BioMedix Inc (2000–2024)
The table below shows the annual net assets of Helix BioMedix Inc from 2000 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $2.08 Million | -29.55% |
| 2023-12-31 | $2.96 Million | -22.23% |
| 2022-12-31 | $3.80 Million | -19.58% |
| 2021-12-31 | $4.73 Million | +111.07% |
| 2020-12-31 | $2.24 Million | +8.94% |
| 2013-12-31 | $2.06 Million | +1658.12% |
| 2012-12-31 | $117.00K | -95.39% |
| 2011-12-31 | $2.54 Million | -47.99% |
| 2010-12-31 | $4.87 Million | +194.31% |
| 2009-12-31 | $-5.17 Million | -201.47% |
| 2008-12-31 | $-1.71 Million | -202.62% |
| 2007-12-31 | $1.67 Million | -40.29% |
| 2006-12-31 | $2.80 Million | -20.46% |
| 2005-12-31 | $3.52 Million | +31.32% |
| 2004-12-31 | $2.68 Million | -8.69% |
| 2003-12-31 | $2.93 Million | +62.28% |
| 2002-12-31 | $1.81 Million | +345.65% |
| 2001-12-31 | $-736.00K | -222.67% |
| 2000-12-31 | $600.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Helix BioMedix Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6142874800.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $49.78K | 2.39% |
| Other Components | $63.46 Million | 3045.28% |
| Total Equity | $2.08 Million | 100.00% |
Helix BioMedix Inc Competitors by Market Cap
The table below lists competitors of Helix BioMedix Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Fundo de Investimento Caixa Cedae
SA:CXCE11
|
$67.42K |
|
Jetblack Corp
PINK:JTBK
|
$67.42K |
|
Cohort
LSE:CHRT
|
$67.49K |
|
CK Infrastructure Holdings Limited
MU:CHH
|
$67.57K |
|
BURA39
SA:BURA39
|
$67.31K |
|
Crossroads Systems Inc
OTCQX:CRSS
|
$67.28K |
|
Grifols SA
MC:GRF-P
|
$67.21K |
|
Alfa Financial Software Holdings PLC
LSE:ALFA
|
$67.16K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Helix BioMedix Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,958,157 to 2,083,978, a change of -874,179 (-29.6%).
- Net loss of 982,339 reduced equity.
- Other factors increased equity by 108,160.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-982.34K | -47.14% |
| Other Changes | $108.16K | +5.19% |
| Total Change | $- | -29.55% |
Book Value vs Market Value Analysis
This analysis compares Helix BioMedix Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.77x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has increased from 0.19x to 0.77x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2006-12-31 | $37.57 | $7.18 | x |
| 2007-12-31 | $19.94 | $7.18 | x |
| 2008-12-31 | $-20.05 | $7.18 | x |
| 2009-12-31 | $-60.45 | $7.18 | x |
| 2010-12-31 | $53.91 | $7.18 | x |
| 2011-12-31 | $15.30 | $7.18 | x |
| 2020-12-31 | $10.91 | $7.18 | x |
| 2021-12-31 | $21.05 | $7.18 | x |
| 2022-12-31 | $16.93 | $7.18 | x |
| 2023-12-31 | $13.16 | $7.18 | x |
| 2024-12-31 | $9.27 | $7.18 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Helix BioMedix Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -47.14%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -122.15%
- • Asset Turnover: 0.36x
- • Equity Multiplier: 1.06x
- Recent ROE (-47.14%) is above the historical average (-74.95%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2006 | -136.82% | -5396.57% | 0.02x | 1.09x | $-4.11 Million |
| 2007 | -205.54% | -740.18% | 0.23x | 1.21x | $-3.60 Million |
| 2008 | 0.00% | -802.22% | 0.21x | 0.00x | $-4.34 Million |
| 2009 | 0.00% | -964.82% | 0.19x | 0.00x | $-3.26 Million |
| 2010 | -158.19% | -905.36% | 0.16x | 1.07x | $-8.20 Million |
| 2011 | -98.16% | -131.58% | 0.64x | 1.17x | $-2.74 Million |
| 2020 | -82.76% | -101.01% | 0.33x | 2.52x | $-2.08 Million |
| 2021 | -28.76% | -57.32% | 0.49x | 1.02x | $-1.83 Million |
| 2022 | -31.34% | -67.94% | 0.45x | 1.03x | $-1.57 Million |
| 2023 | -35.70% | -105.85% | 0.33x | 1.02x | $-1.35 Million |
| 2024 | -47.14% | -122.15% | 0.36x | 1.06x | $-1.19 Million |
Industry Comparison
This section compares Helix BioMedix Inc's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $59,082,939
- Average return on equity (ROE) among peers: -341.19%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Helix BioMedix Inc (HXBM) | $2.06 Million | -136.82% | 0.10x | $67.36K |
| Aadi Bioscience Inc (AADI) | $-124.24K | 0.00% | 0.00x | $17.03 Million |
| America Great Health (AAGH) | $-992.37K | 0.00% | 0.00x | $2.12 Million |
| Ascentage Pharma Group International (AAPG) | $70.63 Million | -1310.51% | 34.40x | $2.25 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $59.18 Million |
| ABIVAX Société Anonyme (AAVXF) | $196.01 Million | -75.37% | 0.67x | $377.86 Million |
| Abcellera Biologics Inc (ABCL) | $10.25 Million | -21.57% | 1.29x | $738.02 Million |
| Abeona Therapeutics Inc (ABEO) | $489.00K | -1919.02% | 38.85x | $202.79 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $108.65 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $176.18 Million | -62.76% | 0.23x | $345.85 Million |